Brexit: The UK MHRA's View Of The Elephant In The Room
UK preparations for a Brexit deal with the EU are not following the smooth path that the UK government would like, as more and more complications emerge. The executive bodies charged with translating Brexit seamlessly into UK policy and law can only watch and wait, but the MHRA, for one, has a strong feel for what is best for UK health care stakeholders.
You may also be interested in...
2017 is going to be a pivotal year for EU medtech regulations. We are expecting the new Medical Devices Regulation and IVD Regulation to take effect. But there are some big concerns and uncertainties at the center of it all.
Confusing and ineffective channels of innovation adoption and a lack of funding hamper the UK's reputation as one of the world's health care capitals and a driver of care excellence – in spite of its global brands, NICE, MHRA and the NHS itself. But changes that should transform market access are in place and are worthy of close attention in the next two to three years.
An opinion from an advocate general at the EU Court of Justice could have an impact on whether TÜV Rheinland is found liable and might have to pay damages in the PIP breast implant case, raising broader issues about liability insurance for notified bodies.